EVENT March 11, 2017

Preliminary Data with Bertilimumab in an Open Label Phase 2a Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid, presented at the American Academy of Dermatology 2017 Annual Meeting in Orlando, FL.

Preliminary Data with Bertilimumab in an Open Label Phase 2a Study in Bullous Pemphigoid were presented last Saturday at the American Academy of Dermatology 2017 Annual Meeting in Orlando, FL. Pr. Neil Korman, MD, PhD, FAAD spoke on March, 4th 2017 at the F076 – AUTOIMMUNE BLISTERING DISEASES: WHAT’S NEW scientific session, directed by Pr. […]

Keep Reading

EVENT February 24, 2017

IMNP Dermatology (Bullous Pemphigoid and Atopic Dermatitis) Educational Symposium

The following subjects in dermatology will be presented and discussed: The Need for New Therapies to Treat Bullous Pemphigoid and Atopic Dermatitis – Neil J. Korman, MD, PhD, Case Western, Cleveland, OH Rationale for Using Bertilimumab in a Bullous Pemphigoid Trial – Animesh A. Sinha, MD, PhD, University at Buffalo, NY Novel Pathogenic Developments in Atopic Dermatitis and Implications for […]

Keep Reading

EVENT January 27, 2017

Immune Pharmaceuticals Satellite Symposium at the International Symposium on Acute Leukemias XVI

Immune will hold a Satellite Symposium on February 20th, 2017 at the International Symposium on Acute Leukemias (ISAL) XVI in Munich, Germany. The satellite symposium is entitled: “Reinforcing the Efficacy of Immunotherapy for the maintenance of remission in AML with Ceplene” and will take place on Monday February 20th, 2017 from 12:45 – 13:45 CET in Lecture Hall III/IV in […]

Keep Reading

EVENT January 4, 2017

R&D Trends: What’s Changed in the Pharma Pipeline?

Panel discussion at the East/West CEO Conference, San Francisco, January 8th, 3:00-3:30 pm Susan Herbert, EVP, Global Head, Marketing & Strategy, EMD Serono; Tom Heyman, President, Johnson & Johnson Innovation, JJDC; Vivek Ramaswamy, CEO, Roivant Sciences and Axovant Sciences; Daniel Teper, CEO, Immune Pharmaceuticals Moderator: Joel Marcus, CEO, Alexandria Ventures Read more details about the conference here.

Keep Reading

EVENT December 6, 2016

Immuno Oncology R&D Update

We will be having an Immuno Oncology R&D update, this coming Thursday, December 8th. The event will be broadcasted on Facebook Live as a live interview with Dr Daniel Teper, Dr Monica Luchi, and Dr Miri Ben Ami, moderated by John Persino.  In addition, we will share on our website a Q&A with experts and management […]

Keep Reading

EVENT June 3, 2016

Immune to Attend the 2016 BIO International Convention

2016 BIO International Convention Moscone Center, San Fransisco June 6-9, 2016 If you would like to schedule a meeting with IMMUNE, please contact us through the website or email Danielle Shapira at Danielle.shapira@immunepharma.com The BIO International Convention returns to the birthplace of biotech, San Francisco, California for 2016! The Bay Area region continues to grow and […]

Keep Reading

EVENT June 3, 2016

CEO Dr. Daniel Teper and Dr. Mark Levitt, SVP Clinical Affairs, Oncology to attend the 2016 ASCO Annual Meeting

Please join us at the 2016 ASCO Annual Meeting in McCormick Place, Chicago on June 3, 2016. The 2016 ASCO Annual Meeting program offers a variety of engaging session formats—from debates, tumor boards, and abstract presentations to Meet the Professor sessions and case-based learning—providing attendees with expert insight and global perspectives on treatment and communication strategies. Sessions integrate […]

Keep Reading

EVENT June 3, 2016

CEO Dr. Daniel Teper to Present at the 2nd Annual Immuno-Oncology BD&L and Investment Forum

2nd Annual Immuno-Oncology BD&L and Investment Forum Hyatt Chicago Magnificent Mile June 3, 2016 CEO Dr. Daniel Teper to present at 12 PM The 2nd Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding & investment. We expect […]

Keep Reading